Deepti Jain - 19 May 2026 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Reporting relationship: Director
Issuer ticker: TMCI
Reported as of: 19 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 May 2026, 21:00:06 UTC
Prior SEC filing: 21 May 2025
Source filing: View source filing
Reporting owner signature: /s/ Lisa Taylor as Attorney-in-fact for Deepti Jain

Key filing fact

Deepti Jain filed Form 4 for TREACE MEDICAL CONCEPTS, INC. (TMCI) on 19 May 2026.

Key facts

This page summarizes Deepti Jain's Form 4 filing for TREACE MEDICAL CONCEPTS, INC. (TMCI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 21:00.

Change

Previous filing in this sequence was filed on 21 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001840203 Primary reporting owner

Jain Deepti

Relationship: Director
Address: C/O TREACE MEDICAL CONCEPTS, INC., 100 PALMETTO PARK PLACE, PONTE VEDRA
Signature: /s/ Lisa Taylor as Attorney-in-fact for Deepti Jain
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TMCI transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %: +43%
Price: $0.000000^*
Shares after: 100,243
Date: 19 May 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 19, 2027 or (b) the date of the 2027 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date.

Footnote F2

Includes 30,000 restricted stock units.